Tenaya Therapeutics reports Q4 2024 net loss of $23.8M; cash runway extended to mid-2026 after $48.9M offering

Tenaya Therapeutics, Inc.

Net loss of $23.8M ($0.28 per share) for Q4 2024; full-year net loss $111.1M ($1.31 per share).
Cash and investments $61.4M at Dec 31, 2024; after $48.9M March 2025 offering, runway into mid-2026.
Dosing initiated in Cohort 2 (6E13 vg/kg) of MyPEAK-1 Phase 1b/2 trial for TN-201; Cohort 1 data accepted as ACC late-breaker.
First patient dosed in RIDGE-1 Phase 1b trial for TN-401; initial data expected in 2H25; CIRM awarded $8M grant.
Hiro Higa promoted to SVP, Finance and interim principal accounting officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.